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Abstract
Objective: Both depression and use of antidepressants have been negatively associated with bone mineral density (BMD) but
mainly in studies among postmenopausal women. Therefore, the aim of this study was to investigate these relationships in men.
Methods: Between 2006 and 2011, 928 men (aged 24-98 years) from the Geelong Osteoporosis Study completed a comprehensive
questionnaire, clinical measurements and had BMD assessments at the forearm, spine, total hip and total body. Major depressive
disorder (MDD) was identified using a structured clinical interview (SCID-I/NP). The cross-sectional associations between BMD
and both MDD and antidepressant use were analyzed using multivariable linear regression. Results: Of the study population, 84
(9.1%) men had a single MDD episode, 50 (5.4%) had recurrent episodes and 65 (7.0%) were using antidepressants at the time
of assessment. Following adjustments, recurrent MDD was associated with lower BMD at the forearm and total body (-6.5%,
P=0.033 and -2.5%, P=0.033, respectively compared to men with no history of MDD), while single MDD episodes were associated
with higher BMD at the total hip (+3.4%, P=0.030). Antidepressant use was associated with lower BMD only in lower-weight
men (<75-110 kg depending on bone site). Conclusions: Both depression and use of antidepressants should be taken into account
as possible risk factors for osteoporosis in men. 
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Introduction
Osteoporosis, a disease characterized by low bone mineral
density (BMD) (i.e. <-2.5 standard deviation (SD) from the
young adult mean), is a common skeletal disorder with over
75 million people suffering worldwide1. It is a silent disorder,
expressed mainly in later life, as evidenced by fragility frac-
tures. In people aged 50 years or older, osteoporosis is one of
the major health disorders: approximately 7% of men and 22%
of women are affected in Europe1 and similarly, 6% of men
and 23% of women in Australia2. In the year 2010, approxi-
mately 3.5 million osteoporotic fractures occurred in Europe,
of which 0.6 million were hip fractures1. Hip fracture is the
most serious outcome often requiring long-term hospitaliza-
tion3. It can be also a risk factor for poorer health and increased
mortality4-6. Though women are at an higher risk of osteoporo-
sis and fractures than men, men suffer more serious outcomes,
with a 2-fold higher mortality risk after fracture4,6.
Risk factors for low BMD and subsequent fracture include
low body mass, previous fracture, female sex and menopause,
low calcium and vitamin D intake, smoking, high alcohol con-
sumption, physical inactivity and use of certain medicines such
as glucocorticoids, some psychotropics (e.g. antipsychotics)
and paracetamol7-9. In addition to lifestyle and nutrition, a
number of diseases can promote low BMD. For example type
1 diabetes10, inflammatory bowel disease11 and schizophrenia12
have been linked with reduced BMD. A number of cross-sec-
tional studies have shown this to be true for depression also
regardless of gender. A 2.1%13 and 2.8%14 lower total hip BMD
has been seen among men with clinical depression compared
to those without. In addition to clinical depression, also milder
depressive symptoms, stress, anxiety and low well-being15-18
has been shown to affect bone negatively. Furthermore, the use
of antidepressants, in particular selective serotonin reuptake
inhibitors (SSRI), has also been associated with reduced
BMD19-21 although the mechanism of action is not clearly ev-
idenced. Reduction in bone mass may be attributed to disease
and medication related processes and/or modifiable lifestyle
factors associated with psychopathology22. 
In the present study, we investigated the relationship be-
tween depression, antidepressant use and BMD in a population
based sample of men. We also examined the role of potential
confounders in any observed associations.
Materials and methods
Study design and subjects
This cross-sectional study examined data collected from
men participating in the Geelong Osteoporosis Study (GOS),
a large, ongoing, population-based study located in south-east-
ern Australia23. During 2001-2006, 1,540 adult men were ran-
domly recruited from the electoral rolls for the Barwon
Statistical Division (response 67%) and 978 of them returned
for 5-year follow-up assessments between 2006 and 2011 (re-
sponse rate 81% of eligible men). Data were collected at one
center only, Barwon Health, Geelong. Utilizing data from the
5-year follow-up assessment, participants whose BMD data
was available were included to the analyses, resulting in a final
sample of 928 men, aged 24-98 years. The study was approved
by the Human Research Ethics Committee at Barwon Health
and all participants provided written, informed consent.
Clinical measurements
Areal BMD (g/cm2) was measured at the ultradistal forearm,
lumbar spine (posterior-anterior projection, L2-L4), total hip and
total body using dual-energy X-ray absorptiometry (DXA;
Prodigy Pro). Trained technicians carried out all examinations
and performed daily calibrations of the densitometers with equip-
ment-specific phantoms. At the time of DXA, height and weight
were measured to the nearest 0.1 cm and 0.1 kg, respectively.
Questionnaire data
Data on demographic, health, medication and lifestyle fac-
tors were obtained. Area-based socio-economic status (SES)
was ascertained using Socio-Economic Index For Areas
(SEIFA) index scores, based on the Australian Bureau of Sta-
tistics Census 2006 data. It was used to derive an Index of Rel-
ative Socio-economic Advantage and Disadvantage (IRSAD)
score accounting for income, and type of occupation. A low
score identifies the most disadvantaged (quintile 1) and a high
score the most advantaged (quintile 5). 
A lifetime history of MDD was assessed using the Struc-
tured Clinical Interview for Diagnostic and Statistical Manual
of Mental Disorders (Fourth Edition, Non-patient edition;
SCID-I/NP)24 by trained personnel. Participants were divided
into three groups: no history of MDD, a single episode or re-
current (≥2) episodes of MDD.
Medication use was classified as current if used at the time
of assessment and categorized into subgroups of antidepres-
sants (including SSRIs, tricyclic antidepressants (TCA) and
serotonin-norepinephrine reuptake inhibitors (SNRI)), oral
glucocorticoids, gonadal hormones, bisphosphonates, calcium
and vitamin D supplements. Habitual physical activity level
was classified as active if light or vigorous exercise was per-
formed; otherwise participants were classified as sedentary.
Dietary calcium intakes (mg/day) and alcohol consumption
were assessed using the validated Cancer Council food fre-
quency questionnaire (FFQ)25 which considered the partici-
pants usual eating habits over the previous 12 months. The
Abbreviations
BMD bone mineral density
GOS Geelong Osteoporosis Study
MDD major depressive disorder
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressants
SNRI serotonin-norepinephrine reuptake inhibitor
AD antidepressants
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latter was calculated as grams of pure alcohol intake per day
(g/day). Current smoking status (no/yes) was self-reported. 
Statistical analyses
Statistical analyses were performed using the SPSS statis-
tical package 19.0 for Windows (SPSS Inc., Chicago, IL,
USA). Differences between MDD status groups (no MDD his-
tory / single episode / recurrent episodes) were examined using
ANOVA for continuous variables and Chi-squared tests
(Fisher’s Exact Test) for categorical variables.
Univariate and multiple linear regression techniques were
used to determine the association between exposure (i.e. his-
tory of MDD episodes or use of antidepressants) and outcome
(i.e. BMD at the forearm, lumbar spine, total hip or total body).
Age, weight, height, smoking, activity level, calcium intake,
alcohol intake, socio-economic status, current use of bisphos-
phonates, corticosteroids, gonadal hormones, calcium or vita-
min D supplements were each explored as effect modifiers
with MDD episodes and antidepressant use regressed on BMD
at each site and included in the final model if significant
(p<0.05).
Results
Baseline characteristics
Of the 928 men included in the analyses, 794 (85.6%) had no
lifetime history of MDD, 84 (9.1%) had a single MDD episode
and 50 (5.4%) had recurrent episodes. Furthermore, 7.0%
(65/928) men were currently using antidepressants; 5.1%
(47/928) used SSRIs, 1.0% (9/928) TCAs and 1.0% (9/928)
SNRIs. Characteristics of the study population are shown in
Table 1. Differences were identified across the groups in regards
to age, height, BMD (forearm, total hip and total body), nutri-
tional calcium intake and use of antidepressant and calcium/vi-
tamin D supplements; otherwise the groups were similar.
Univariate and multivariable analyses
In the univariate models, men meeting criteria for a single
MDD episode had higher forearm, total hip and total body
Characteristics All No MDD Single MDD Recurrent MDD P valuea
n=928 n=794 n=84 n=50
Age (yr) 60.0 (46.3-73.2) 60.9 (47.6-75.1) 51.6 (43.3-64.1)* 55.4 (38.3-64.0)* <.001
Height (cm) 174.9 (7.2) 174.7 (7.3) 175.3 (6.9) 177.2 (6.4)* .050
Weight (kg) 84.3 (14.5) 83.9 (14.4) 86.6 (16.5) 87.3 (12.6) .087
BMD (g/cm2)
Forearm 0.419 (0.064) 0.418 (0.064) 0.435 (0.064)* 0.409 (0.056) .031
Lumbar spine 1.293 (0.198) 1.298 (0.201) 1.281 (0.191) 1.244 (0.166) .16
Total hip 1.066 (0.148) 1.062 (0.147) 1.108 (0.154)* 1.058 (0.148) .027
Total body 1.241 (0.110) 1.239 (0.110) 1.266 (0.115)* 1.230 (0.091) .088
Calcium intake (mg/day) 934 (366) 923 (354) 958 (441) 1080 (406)* .015
Alcohol intake (g/day) 12.0 (2.1-28.7) 11.8 (2.1-28.2) 15.1 (2.7-36.1) 17.7 (1.2-37.2) .20
Socio-economic status .66
Quintile 1 (lowest) 150 (16.2%) 129 (16.2%) 14 (16.7%) 7 (14.0%)
Quintile 2 186 (20.0%) 160 (20.2%) 16 (19.0%) 10 (20.0%)
Quintile 3 179 (19.3%) 160 (20.2%) 12 (14.3%) 7 (14.0%)
Quintile 4 203 (21.9%) 168 (21.2%) 19 (22.6%) 16 (32.0%)
Quintile 5 210 (22.6%) 177 (22.3%) 23 (27.4%) 10 (20.0%)
Smokers (current) 104 (11.3%) 86 (10.9%) 14 (16.9%) 4 (8.0%) .20
Physically active 660 (71.4%) 570 (72.2%) 58 (69.0%) 32 (64.0%) .41
Medication (current)
Antidepressants 65 (7.0%) 38 (4.8%) 13 (15.5%)* 14 (28.0%)* <.001
SSRI 47 (5.1%) 27 (3.4%) 11 (13.1%) 9 (18.0%) <.001
TCA 9 (1.0%) 7 (0.9%) 1 (1.2%) 1 (2.0%) .72
SNRI 9 (1.0%) 4 (0.5%) 1 (1.2%) 4 (8.0%) <.001
Bisphosphonates 15 (1.6%) 12 (1.5%) 1 (1.2%) 2 (4.0%) .38
Corticosteroids 10 (1.1%) 9 (1.1%) 1 (1.2%) 0 (0.0%) .75
Hormone therapy 3 (0.3%) 2 (0.3%) 0 (0.0%) 1 (2.0%) .093
Calcium/Vitamin D 125 (13.5%) 100 (12.6%) 13 (15.5%) 12 (24.0%)* .062
Abbreviations: BMD, bone mineral density; MDD, major depressive disorder; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI serotonin
reuptake inhibitor; TCA, tricyclic antidepressant. aBetween MDD status. *P-value<0.05 compared to men with no MDD (from Pearson chi-
square / Anova).
Table 1. Characteristics of the study population overall and according to MDD status. Values are given as median (interquartile range), mean
(standard deviation) or n (%).
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BMD (B=0.018, B=0.046 and B=0.027, respectively) com-
pared to men with no history of MDD (Table 2). There was a
non-significant trend for men meeting criteria for recurrent
MDD to have lower spine BMD (B=-0.053) compared to men
with no MDD history. 
After age- and weight-adjustments (multivariable model 1),
recurrent MDD was significantly associated with lower fore-
arm and total body BMD (B= -0.018 and B= -0.032, respec-
tively) and tended to be associated with spine and total hip
BMD (B= -0.050 and B= -0.031, respectively) (Table 2). 
Univariate models Multivariable model 1 Multivariable model 2 Final model
BMD/MDD status B 95% CI P value B 95% CI P value B 95% CI P value B 95% CI P value
Forearm 
(Constant) 0.418 0.413, 0.422 <.001 0.352 0.323, 0.380 <.001 0.360 0.331, 0.390 <.001 0.475 0.362, 0.587 <.001
Single MDD 0.018 0.003, 0.032 .016 0.009 -0.004, 0.022 .19 0.010 -0.003, 0.024 .15 0.011 -0.003, 0.024 .11
Recurrent MDD -0.009 -0.027, 0.010 .36 -0.018 -0.035, -0.001 .038 -0.019 -0.036, -0.001 .037 -0.020 -0.038, -0.002 .033
Lumbar spine 
(Constant) 1.298 1.284, 1.311 <.001 0.907 0.812, 1.002 <.001 0.929 0.831, 1.026 <.001 0.608 0.241, 0.974 .001
Single MDD -0.016 -0.062, 0.029 .48 -0.007 -0.051, 0.037 .75 -0.003 -0.047, 0.042 .91 0.005 -0.040, 0.049 .83
Recurrent MDD -0.053 -0.110, 0.004 .067 -0.050 -0.106, 0.005 .073 -0.046 -0.103, 0.011 .11 -0.047 -0.106, 0.012 .12
Total hip
(Constant) 1.062 1.051, 1.072 <.001 0.837 0.770, 0.904 <.001 0.865 0.797, 0.933 <.001 1.262 1.006, 1.517 <.001
Single MDD 0.046 0.012, 0.080 .008 0.029 -0.001, 0.060 .062 0.034 0.003, 0.065 .030 0.034 0.003, 0.064 .030
Recurrent MDD -0.004 -0.047, 0.039 .85 -0.031 -0.070, 0.007 .11 -0.028 -0.068, 0.011 .16 -0.029 -0.069, 0.012 .17
Total body
(Constant) 1.239 1.231, 1.247 <.001 0.985 0.940, 1.031 <.001 1.002 0.956, 1.048 <.001 0.945 0.769, 1.120 <.001
Single MDD 0.027 0.002, 0.052 .037 0.012 -0.009, 0.033 .27 0.014 -0.007, 0.035 .19 0.017 -0.004, 0.038 .12
Recurrent MDD -0.009 -0.040, 0.023 .59 -0.032 -0.059, -0.006 .017 -0.032 -0.059, -0.005 .020 -0.031 -0.059, -0.003 .033
Abbreviations: BMD, bone mineral density; MDD, major depressive disorder. Notes: Multivariable model 1 is adjusted for age and weight. Multivariable model 2 is adjusted
for age, weight and current use of antidepressant. Final model is adjusted for age, weight, height, nutritional calcium intake and current use of antidepressants, bisphospho-
nates and calcium or vitamin D supplements.
Table 2. Unadjusted and adjusted linear regression analyses between MDD status and forearm, spine, total body and total hip BMD (g/cm2).
Univariate models Multivariable model 1 Final model
BMD/factors B 95% CI P value B 95% CI P value B 95% CI P value
Forearm 
(Constant) 0.419 0.415, 0.424 <.001 0.360 0.331, 0.389 <.001 0.475 0.364, 0.587 <.001
Use of AD -0.009 -0.026, 0.007 .27 -0.131 -0.224, -0.037 .006 -0.141 -0.233, -0.049 .003
Weight 0.001 0.001, 0.002 <.001 0.001 0.001, 0.001 <.001 0.001 0.001, 0.002 <.001
AD*Weight - - - 0.001 0.000, 0.003 .010 0.002 0.001, 0.003 .003
Lumbar spine 
(Constant) 1.296 1.282, 1.309 <.001 0.924 0.827, 1.021 <.001 0.608 0.241, 0.974 .001
Use of AD -0.036 -0.086, 0.014 .16 -0.326 -0.622, -0.029 .032 -0.333 -0.627, -0.039 .027
Weight 0.003 0.002, 0.004 <.001 0.003 0.002, 0.004 <.001 0.002 0.001, 0.003 <.001
AD*Weight - - - 0.003 0.000, 0.007 .062 0.004 0.000, 0.007 .043
Total hip
(Constant) 1.068 1.058, 1.079 <.001 0.868 0.799, 0.936 <.001 1.262 1.006, 1.517 <.001
Use of AD -0.040 -0.077, -0.002 .039 -0.398 -0.603, -0.194 <.001 -0.414 -0.615, -0.213 <.001
Weight 0.004 0.004, 0.005 <.001 0.004 0.003, 0.004 <.001 0.004 0.003, 0.005 <.001
AD*Weight - - - 0.004 0.002, 0.007 .001 0.004 0.002, 0.007 <.001
Total body
(Constant) 1.242 1.235, 1.250 <.001 1.001 0.955, 1.048 <.001 0.945 0.769, 1.120 <.001
Use of AD -0.019 -0.047, 0.009 .18 -0.229 -0.371, -0.087 .002 -0.241 -0.382, -0.101 .001
Weight 0.004 0.004, 0.005 <.001 0.004 0.003, 0.004 <.001 0.004 0.003, 0.004 <.001
AD*Weight - - 0.002 0.001, 0.004 .004 0.003 0.001, 0.004 .001
Abbreviations: AD, antidepressants (current, no/yes); BMD, bone mineral density. Notes: Multivariable model 1 is adjusted for age and weight. Final
model is adjusted for age, weight, height, nutritional calcium intake, MDD status, current use of bisphosphonates and calcium or vitamin D supplements.
Table 3. Unadjusted and adjusted linear regression analyses between use of antidepressant and forearm, spine, total body and total hip BMD (g/cm2).
P.H. Rauma et al.: Depression, antidepressants and bone
181
Further adjustment for antidepressant use (multivariable model
2) is shown in Table 2. In the final model, recurrent MDD was
associated with lower forearm and total body BMD (B= -0.020
and B= -0.031, respectively) (Table 2), which corresponds to
6.5% lower forearm and 2.5% lower total body BMD than men
with no MDD history. Similarly, recurrent MDD tended to be
associated with lower spine BMD (B= -0.047, corresponding
-4.0%). A single MDD episode was associated with higher ad-
justed total hip BMD (B=0.034, corresponding +3.4%), but no
association was evident for the other sites (Table 2). These
models include both antidepressant use and the interaction
term between weight and antidepressant use. Still, MDD was
independently associated with BMD. There was no significant
interaction between antidepressant use and MDD on BMD.
In univariate models, antidepressant users had lower total
hip BMD (B= -0.040) than non-users (Table 3). Weight was
an effect modifier in the relationship between antidepressant
use and BMD (Table 3). In the final models, lower BMD was
associated with antidepressant use in those with lower body
weight (<75-110 kg depending on bone site) (Table 4).
Discussion
Recurrent MDD was associated with lower forearm and
total body BMD in the present study in men. In contrast, single
MDD was associated with higher BMD at the total hip. Fur-
thermore, use of antidepressants was associated with lower
BMD at all measured sites (i.e. forearm, lumbar spine, total
hip and total body) among men with low body weight only.
These associations were independent of age, anthropometry,
socio-economic status, medication and lifestyle factors (i.e.
calcium intake, alcohol use, smoking, physical activity).
Our study showed a 6.5% decrease in forearm BMD and
2.5% decrease in total body BMD in men with recurrent MDD
episodes. Literature shows that a change of 3-6% is required
for clinical significance26. The present study partly supports
Multivariable model 1 Final model
BMD (g/cm2) BMD (g/cm2)
BMD site Non-users Users diff %a Non-users Users diff %a
Forearm
60 kg 0.360 0.289 -19.7 0.266 0.245 -7.9
70 kg 0.370 0.309 -16.5 0.276 0.275 -0.4
80 kg 0.380 0.329 -13.4 0.286 0.305 6.6
90 kg 0.390 0.349 -10.5 0.296 0.335 13.2
100 kg 0.400 0.369 -7.7 0.306 0.365 19.3
110 kg 0.410 0.389 -5.1 0.316 0.395 25.0
Lumbar spine 
60 kg 0.985 0.839 -14.8 1.103 1.010 -8.4
70 kg 1.015 0.899 -11.4 1.123 1.070 -4.7
80 kg 1.045 0.959 -8.2 1.143 1.130 -1.1
90 kg 1.075 1.019 -5.2 1.163 1.190 2.3
100 kg 1.105 1.079 -2.4 1.183 1.250 5.7
110 kg 1.135 1.139 0.4 1.203 1.310 8.9
Total hip
60 kg 0.989 0.831 -16.0 0.948 0.774 -18.4
70 kg 1.029 0.911 -11.5 0.988 0.854 -13.6
80 kg 1.069 0.991 -7.3 1.028 0.934 -9.1
90 kg 1.109 1.071 -3.4 1.068 1.014 -5.1
100 kg 1.149 1.151 0.2 1.108 1.094 -1.3
110 kg 1.189 1.231 3.5 1.148 1.174 2.3
Total body
60 kg 1.181 1.072 -9.2 1.120 1.059 -5.4
70 kg 1.221 1.132 -7.3 1.160 1.129 -2.7
80 kg 1.261 1.192 -5.5 1.200 1.199 -0.1
90 kg 1.301 1.252 -3.8 1.240 1.269 2.3
100 kg 1.341 1.312 -2.2 1.280 1.339 4.6
110 kg 1.381 1.372 -0.7 1.320 1.409 6.7
Abbreviations: BMD, bone mineral density. Notes: Multivariable model 1 is adjusted for age and weight. Final model is adjusted for age, weight,
height, nutritional calcium intake, MDD status, current use of bisphosphonates and calcium or vitamin D supplements. * from linear regression;
a % difference when comparing the BMD of antidepressant users to non-users (calculated as follows BMDusers-BMDnon-users / BMDnon-users*100%).
Table 4. Adjusted calculated* results according to body weight for antidepressant users and non-users by BMD site (g/cm2).
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the previous results using data from the GOS showing lower
adjusted femoral neck and spine BMD in men with self-re-
ported depression compared to men with no reported history27.
However, in the current study, we were able to determine the
number of episodes of clinically diagnosed MDD and investi-
gate whether this affected the relationship of interest. In gen-
eral, both clinically diagnosed depression and depressive
symptoms have been associated with low BMD among men13-
15,28-30. Associations have been seen using total hip13,14, spine30
and forearm15 sites. In contrast to the present study, Wong et
al13 found no association with depression using total body
BMD, but akin to the present study, no association with spine
BMD was seen either. Charles et al31 also found no cross-sec-
tional association between BMD and depressive symptoms in
men. For most of these studies, the findings were independent
of antidepressant use13,15,28-30 or specifically SSRIs31, with the
exception of one study of young adults where antidepressant
users was not excluded nor antidepressant use statistically con-
trolled for14.
In most of the studies among females or both genders
pooled, SSRIs have appeared to be negatively associated with
BMD9,19,30,32 but not in all33. In contrast, TCAs have been
shown to have no effect32 or even a positive effect on bone9.
Among men, SSRIs have also been shown to negatively affect
bone at different sites in both male adolescents34 and in older
men21,35. Similarly, it has been shown that antidepressants have
a negative effect on bone in men with low weight36. Others
have shown no association between any antidepressants30 and
TCA21,35 use and bone. In our study, we pooled antidepressant
use due to power constraints and recognize that if different an-
tidepressant subgroups differentially affect bone, their effect
is likely to be diluted. However, in the present study majority
(72%) was taking SSRIs, thus, we can assume that possible
contradictory results from use of other antidepressants are
likely to be small.
The results of the present study support the hypothesis that
recurrent episodes of MDD and antidepressants independently
have a negative effect on BMD, although the effect of antide-
pressants was dependent on body weight. It is not clear why
single episode MDD in men was positively associated with
total hip BMD. It is possibly a spurious finding. However, we
do not know the duration or timing of the single episode of de-
pression in these men. It is possible that they may have already
had successful treatment for depression in the past without re-
currence or the episode may have been short in duration and of
mild severity. In addition, the group with no MDD episode may
also include participants with sub-threshold depression or pro-
longed stress without diagnosis and treatment37. Moreover, a
single-episode of depression may be qualitatively different,
being more psychological and related to an adjustment reaction
to stressors, as opposed to recurrent depression, which is likely
to be more biological and activate neuroprogressive pathways
such as inflammation, oxidative stress and apoptosis, which can
similarly predispose individuals to osteoporosis38-40.
Depression causes chronic stress, which stimulates cortisol
and catecholamine (e.g. noradrenaline) secretion resulting in
bone loss7,40. Increased levels of bone resorption markers41,42
and proinflammatory cytokines43,44 have also been found in as-
sociation with depression. Studies have shown that bone and
immune cells are functionally interconnected45. They are de-
rived from same progenitors, share a common microenviron-
ment and are influenced by similar mediators45. Activated T
cells are the most powerful cells during inflammation which
contribute to enhanced osteoclastogenesis both by increasing
the production of bone resorbing cytokines and the numbers
of osteoclast precursors45. Activation of inflammatory markers
occurs also in milder depression and in the presence of stress,
especially if the effect is prolonged. Low subjective well-being
indicated as life dissatisfaction has been longitudinally asso-
ciated with both lower BMD and greater bone loss in post-
menopausal women - independent of severe depression and
antidepressant treatment16. Among young adults, depressive
symptoms in combination with high work-related stress have
been associated with lower BMD17. Previously, utilizing the
present male study population depressive symptoms have been
linked with reduced BMD at the lumbar spine and femoral
neck27. Oxidative stress is another possible mechanism of ac-
tion. It can impact on bone directly by both promoting osteo-
clast formation and activity and inhibiting osteoblast
differentiation and activity46. Finally, various modifiable
lifestyle factors linked with depression have physiologic con-
sequences, which in turn are likely to affect bone metabolism22.
In the present study we found that body weight acted as an
effect modifier in the association between antidepressant use
and BMD. A similar finding was seen in our previous study
on the effect of antidepressant use on heel quantitative ultra-
sound measures in men36. The effect of body weight on bone
might also be explained by the amount of fat tissue. Adipocytes
secrete leptin, which is involved in stimulating food intake and
energy expenditure47. High leptin concentration has been found
to be beneficial to bone mass48,49. In addition to indirect effects
via the central nervous system48, leptin receptors have been
found to be expressed in osteoblasts where leptin seems to di-
rectly increase proliferation and differentiation50,51. However,
also differing effects of body fat on bone have been shown.
Subcutaneous fat, the main source of leptin and adiponectin,
has been shown to be beneficial to bone, whereas visceral fat
has been shown to negatively affect bone due to its ability to
produce more pro-inflammatory cytokines52,53. Serotonin re-
ceptors and transporters have also been found to be expressed
in adipocytes54,55. However, the effect of antidepressants influ-
encing bone metabolism via adipocytes is unclear and both in-
creased56,57 and decreased58 or non-changed57 leptin levels
during antidepressant therapy have been seen. Without taking
into account the possible effects of antidepressant medication
on adipocytes, participants with higher body weight are likely
to have more fat tissue with higher concentrations of
adipocytes and leptin, which might overshadow the negative
effects of antidepressant use on bone. Furthermore, the positive
association with BMD in participants with higher weight might
also reflect the adaptive effect of load bearing on bone
turnover. Finally, there may be other unclear confounding
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mechanisms operative between bone, body mass and use of
antidepressants. In our cross-sectional study, we did not ob-
serve a weight*MDD interaction on BMD. However, we did
not investigate weight change over time.
Strengths of this study include a large population-based
sample of men spanning the full adult age range and ability to
adjust for several confounding factors. Also, the use of struc-
tured diagnostic interviews to determine depression, discrim-
inating between single and recurrent episodes and
investigating several BMD sites are further strengths. A limi-
tation is the cross-sectional, observational study design, which
does not allow the investigation of causality. We classified par-
ticipants as current users only if they reported using medica-
tion at the time of assessment, which may lead to ignoring
users who stopped the use recently or use the medication ir-
regularly. Fracture history had not been considered in the sta-
tistical models and we did not account for weight change as a
confounding factor in the present study. Furthermore, data on
the duration and severity of MDD episodes were not available.
Conclusions
In conclusion, recurrent MDD was evidenced to have a neg-
ative impact on bone. Use of antidepressants was also found
to be negatively associated with BMD among men with lower
body weight. We found that MDD and antidepressant use were
independently associated with BMD; however, separation of
these two issues is difficult. In all, prevention of depression,
its early detection and appropriate medical care are important
issues in the prevention and care of osteoporosis in men.
Lastly, these data raise the issue of screening for BMD in at-
risk populations.
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